Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Cash from Investing Activities data on file, last reported at -$11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 42.94% year-over-year to -$11.3 million; the trailing twelve-month figure through Mar 2026 stood at -$25.8 million (up 94.05% YoY), and the FY2025 full-year result was -$34.3 million, up 91.52% from the prior year.
• Cash from Investing Activities eased to -$11.3 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $8.9 million in Q1 2024 to a low of -$398.5 million in Q3 2024.
• A 5-year average of -$28.5 million and a median of -$4.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 479.64% in 2024, while the deepest fall reached 8652.95% in 2024.
• Tracing ANIP's Cash from Investing Activities over 5 years: stood at -$3.1 million in 2022, then slumped by 52.1% to -$4.8 million in 2023, then sank by 123.5% to -$10.7 million in 2024, then surged by 86.86% to -$1.4 million in 2025, then sank by 707.13% to -$11.3 million in 2026.
• Business Quant data shows ANIP's Cash from Investing Activities at -$11.3 million in Q1 2026, -$1.4 million in Q4 2025, and -$6.2 million in Q3 2025.